An update on the current pharmacotherapy for endometrial cancer

被引:26
作者
de Haydu, Christopher [1 ]
Black, Jonathan D. [2 ]
Schwab, Carlton L. [2 ]
English, Diana P. [2 ]
Santin, Alessandro D. [2 ]
机构
[1] Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, New Haven, CT USA
[2] Yale Univ, Sch Med, Gynecol Oncol Sect, Dept Obstet Gynecol & Reprod Sci, New Haven, CT USA
关键词
targeted therapy; endometrial cancer; chemotherapy; Adjuvant therapy; endometrial pharmacotherapy; hormone therapy; uterine cancer; PHASE-II TRIAL; PERFRINGENS ENTEROTOXIN CPE; DEPENDENT KINASE INHIBITOR; ENDOTHELIAL GROWTH-FACTOR; UTERINE SEROUS CARCINOMA; PTEN EXPRESSION; MEDROXYPROGESTERONE ACETATE; ADJUVANT CHEMOTHERAPY; AKT PHOSPHORYLATION; THERAPEUTIC TARGET;
D O I
10.1517/14656566.2016.1127351
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Endometrial cancer (EC) is the most common gynecologic malignancy in the developed world and is increasing in incidence. While the mainstay of treatment for EC is surgery followed by chemotherapy and/or radiation therapy, the available pharmacotherapies are rapidly and constantly evolving. Understanding these new therapies is an important part of the research and clinical care of women with EC. A review of available literature from MEDLINE (1879-2015) was conducted for the historic treatments and current therapies available for endometrial tumors. Areas covered: This article reviews the current conventional therapies and discusses novel therapeutic agents, some of which are available to clinicians while others are currently being investigated in the preclinical setting. Expert opinion: Genomic and immunohistochemical characterization of endometrial cancer may soon be the best approach for the identification of aggressive forms of tumor. Targeted therapies will soon be standard in the management of endometrial cancer.
引用
收藏
页码:489 / 499
页数:11
相关论文
共 148 条
[1]   Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group [J].
Aapro, MS ;
van Wijk, FH ;
Bolis, G ;
Chevallier, B ;
van der Burg, MEL ;
Poveda, A ;
de Oliveira, CF ;
Tumolo, S ;
di Palumbo, VS ;
Piccart, M ;
Franchi, M ;
Zanaboni, F ;
Lacave, AJ ;
Fontanelli, R ;
Favalli, G ;
Zola, P ;
Guastalla, JP ;
Rosso, R ;
Marth, C ;
Nooij, M ;
Presti, M ;
Scarabelli, C ;
Splinter, TAW ;
Ploch, E ;
Beex, LVA ;
Huinink, WT ;
Forni, M ;
Melpignano, M ;
Blake, P ;
Kerbrat, P ;
Mendiola, C ;
Cervantes, A ;
Goupil, A ;
Harper, PG ;
Madronal, C ;
Namer, M ;
Scarfone, G ;
Stoot, JEGM ;
Teodorovic, I ;
Coens, C ;
Vergote, I ;
Vermorken, JB .
ANNALS OF ONCOLOGY, 2003, 14 (03) :441-448
[2]   Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study [J].
Aghajanian, Carol ;
Sill, Michael W. ;
Darcy, Kathleen M. ;
Greer, Benjamin ;
McMeekin, D. Scott ;
Rose, Peter G. ;
Rotmensch, Jacob ;
Barnes, Mack N. ;
Hanjani, Parviz ;
Leslie, Kimberly K. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (16) :2259-2265
[3]   Improved survival of patients with hypermutation in uterine serous carcinoma [J].
Alessandro, D. Santin ;
Bellone, Stefania ;
Centritto, Floriana ;
Schlessinger, Joseph ;
Lifton, Richard .
GYNECOLOGIC ONCOLOGY REPORTS, 2015, 12 :3-4
[4]   Risk-scoring models for individualized prediction of overall survival in low-grade and high-grade endometrial cancer [J].
AlHilli, Mariam M. ;
Mariani, Andrea ;
Bakkum-Gamez, Jamie N. ;
Dowdy, Sean C. ;
Weaver, Amy L. ;
Peethambaram, Preema P. ;
Keeney, Gary L. ;
Cliby, William A. ;
Podratz, Karl C. .
GYNECOLOGIC ONCOLOGY, 2014, 133 (03) :485-493
[5]   Phase II trial of combination bevacizumab and temsirolimus in the treatment of A recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group study [J].
Alvarez, Edwin A. ;
Brady, William E. ;
Walker, Joan L. ;
Rotmensch, Jacob ;
Zhou, Xun C. ;
Kendrick, James E. ;
Yamada, S. Diane ;
Schilder, Jeanne M. ;
Cohn, David E. ;
Harrison, Charles R. ;
Moore, Kathleen N. ;
Aghajanian, Carol .
GYNECOLOGIC ONCOLOGY, 2013, 129 (01) :22-27
[6]   Alteration of PTEN expression in endometrial carcinoma is associated with down-regulation of cyclin-dependent kinase inhibitor, p27 [J].
An, HJ ;
Lee, YH ;
Cho, NH ;
Shim, JY ;
Kim, JY ;
Lee, C ;
Kim, SJ .
HISTOPATHOLOGY, 2002, 41 (05) :437-445
[7]  
[Anonymous], CHEMOTHERAPY TARGETE
[8]  
[Anonymous], INT J GYNECOL CANC
[9]  
[Anonymous], RADIOLOGY
[10]  
[Anonymous], J CLIN ONCOL S15